NASDAQ:CYCCP Cyclacel Pharmaceuticals (CYCCP) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free CYCCP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.65▼$17.6550-Day Range$5.00▼$6.0352-Week Range$4.25▼$8.07Volume1 shsAverage Volume604 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield3.40%Price TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendHeadlinesSocial MediaStock AnalysisCompetitorsDividendHeadlinesSocial Media Get Cyclacel Pharmaceuticals alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCCP)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story CYCCP Stock News HeadlinesApril 1, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.March 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.February 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceJanuary 19, 2024 | msn.comCyclacel Pharmaceuticals files to sell 411K shares of common stockJanuary 9, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?December 22, 2023 | msn.comCyclacel Pharmaceuticals announces registered direct and private placement offeringDecember 18, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNovember 30, 2023 | finance.yahoo.comCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNovember 14, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.49 misses by $0.13November 14, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsAugust 19, 2023 | finance.yahoo.comCYCC Aug 2023 2.500 callAugust 10, 2023 | finance.yahoo.comQ2 2023 Cyclacel Pharmaceuticals Inc Earnings CallMay 16, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call TranscriptMay 12, 2023 | finance.yahoo.comQ1 2023 Cyclacel Pharmaceuticals Inc Earnings CallMay 11, 2023 | msn.comRecap: Cyclacel Pharmaceuticals Q1 EarningsMay 11, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.47 beats by $0.19May 11, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateMay 5, 2023 | seekingalpha.comCyclacel Pharmaceuticals receives $4.7M R&D tax creditSee More Headlines Receive CYCCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 2/1 Dividend1/19/2024Dividend Payable2/01/2024Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CYCCP CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone+1-908-5177330FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 62)Pres, CEO & Exec. Director Comp: $772.64kMr. Paul McBarron (Age 60)Exec. VP of Fin., CFO, COO, Sec. & Exec. Director Comp: $391.91kDr. Mark H. Kirschbaum M.D. (Age 60)Sr. VP & Chief Medical Officer Comp: $354.73kMs. Gill Christie (Age 64)Director of HR Dr. Robert Westwood Ph.D. (Age 77)Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors CYCCP Stock Analysis - Frequently Asked Questions How often does Cyclacel Pharmaceuticals pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals declared a quarterly dividend on Friday, January 12th. Shareholders of record on Monday, January 22nd will be paid a dividend of $0.15 per share on Thursday, February 1st. This represents a $0.60 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date is Friday, January 19th. Read our dividend analysis for CYCCP. Is Cyclacel Pharmaceuticals a good dividend stock? Cyclacel Pharmaceuticals (NASDAQ:CYCCP) pays an annual dividend of $0.60 per share and currently has a dividend yield of 0.12%. Read our dividend analysis for CYCCP. This page (NASDAQ:CYCCP) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden’s $374B Giveaway Into This SectorDTIThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.